Cerenome vs Lucid Diagnostics
CNSY and LUCD side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CNSY and LUCD compare
Lucid Diagnostics is the larger company, worth 17 times as much as Cerenome ($81.1M against $4.8M).
Lucid Diagnostics grew revenue faster over the last twelve months (24.9% versus −21.0% for Cerenome).
Cerenome keeps more of each dollar of sales as profit, with a net margin of −621% compared with −960% at Lucid Diagnostics.
Cerenome scores higher on the StockData Score (8 against 7 for Lucid Diagnostics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CNSY | LUCD |
|---|---|---|
| Size and price | ||
| Market cap | $4.8M | $81.1M |
| Share price | $0.630 | $0.399 |
| Change, 1 year | −95.1% | −62.7% |
| Change, 5 years | −98.3% | −95.3% |
| Beta (5Y) | 4.92 | 1.89 |
| Employees | 28 | 82 |
| StockData Score | ||
| Total score | 8 (better) | 7 |
| Valuation score | 3 (better) | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 4 | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.1× (better) | 14.9× |
| P/B | 0.9× (better) | 7.4× |
| FCF yield | −492% | – |
| Fair value | $2.14 | $0.298 |
| Margin of safety | 70.5% (better) | −33.9% |
| Growth | ||
| Revenue growth (TTM) | −21.0% | 24.9% (better) |
| Profitability | ||
| Operating margin | −628% (better) | −931% |
| Net margin | −621% (better) | −960% |
| FCF margin | −560% | – |
| Return on equity | −614% | −556% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | −1200.0× (better) | −2815.8× |
| Current ratio | 1.37 (better) | 1.33 |
| Altman Z-score | −58.37 | −13.38 (better) |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 8.3% | 30.2% |
| Held by insiders | 4.2% | 24.8% |
| Insider net buying, 12 months | $0 | $245K (better) |
| Short interest, % of float | 11.6% | 9.8% |
Go deeper
- CNSY stock overview
- CNSY income statement
- CNSY valuation and score
- LUCD stock overview
- LUCD income statement
- LUCD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.